Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 08:00:00 -0400

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 08:00:00 -0400

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Thu, 01 Oct 2026 08:00:00 -0400

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55^th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026.

The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting. IRSF poster presentations are available on Taysha’s

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Thu, 01 Oct 2026 08:00:00 -0400

The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting. IRSF poster presentations are available on Taysha’s

Wolfe Research Starts Taysha Gene Therapies (TSHA) at Outperform

Thu, 17 Sep 2026 05:03:21 -0400

Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Outperform rating.

For an analyst ratings summary and ratings history on Taysha Gene Therapies click here. For more ratings news on Taysha Gene Therapies click here.

Shares of Taysha Gene Therapies closed at $5.08 yesterday.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 08:00:00 -0400

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 08:00:00 -0400

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932199.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932199.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY

Thu, 13 Aug 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922938.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY

Thu, 13 Aug 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922938.html

Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Tue, 11 Aug 2026 16:19:33 -0400

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

Form 10-Q Taysha Gene Therapies, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905715.html

Form 10-Q Taysha Gene Therapies, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905715.html

Form 8-K Taysha Gene Therapies, For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905631.html

Form 8-K Taysha Gene Therapies, For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905631.html

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:00:00 -0400

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced TSHA-102 commercial

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:00:00 -0400

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced TSHA-102 commercial

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:00:00 -0400

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced TSHA-102 commercial

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:00:00 -0400

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through ≥12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced TSHA-102 commercial

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 08:00:00 -0400

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 08:00:00 -0400

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 08:00:00 -0400

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 08:00:00 -0400

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

Tue, 04 Aug 2026 16:00:00 -0400

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.

Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at

StreetInsider.com News Articles

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Wolfe Research Starts Taysha Gene Therapies (TSHA) at Outperform

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY

Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Form 10-Q Taysha Gene Therapies, For: Jun 30

Form 10-Q Taysha Gene Therapies, For: Jun 30

Form 8-K Taysha Gene Therapies, For: Aug 11

Form 8-K Taysha Gene Therapies, For: Aug 11

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11